tbuckley/cabot-search huggingface dataset:
Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts
Authors: Xiao‐Su Zhao, Yan‐Rong Liu, Lan‐Ping Xu, Yu Wang, Xiao‐Hui Zhang, Huan Chen, Yu‐Hong Chen, Wei Han, Yu‐Qian Sun, Chen‐Hua Yan, Xiao‐Dong Mo, Ya‐Zhe Wang, Qiao‐Zhen Fan, Xin‐Yu Wang, Kai‐Yan Liu, Xiao‐Jun Huang, Ying‐Jun Chang
Journal: American Journal of Hematology (2019)

This study evaluated the effects of pretransplantation minimal residual disease (pre‐MRD) on outcomes of patients with acute lymphoblastic leukemia (ALL) who underwent unmanipulated haploidentical stem cell transplantation (haplo‐SCT). A retrospective study including 543 patients with ALL was performed. MRD was determined using multiparametric flow cytometry. Both in the entire cohort of patients and in subgroup cases with T‐ALL or B‐ALL, patients with positive pre‐MRD had a higher incidence of relapse (CIR) than those with negative pre‐MRD in MSDT settings ( P &lt; 0.01 for all). Landmark analysis at 6 months showed that MRD positivity was significantly and independently associated with inferior rates of relapse (HR, 1.908; P = 0.007), leukemia‐free survival (LFS) (HR, 1.559; P = 0.038), and OS (HR, 1.545; P = 0.049). The levels of pre‐MRD according to a logarithmic scale were also associated with leukemia relapse, LFS, and OS, except that cases with MRD &lt;0.01% experienced comparable CIR and LFS to those with negative pre‐MRD. A risk score for CIR was developed using the variables pre‐MRD, disease status, and immunophenotype of ALL. The CIR was 14%, 26%, and 59% for subjects with scores of 0, 1, and 2‐3, respectively ( P &lt; 0.001). Three‐year LFS was 75%, 64%, and 42%, respectively ( P &lt; 0.001). Multivariate analysis confirmed the association of the risk score with CIR and LFS. The results indicate that positive pre‐MRD, except for low level one (MRD &lt; 0.01%), is associated with poor outcomes in patients with ALL who underwent unmanipulated haplo‐SCT.
REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progressive disease of nivolumab (NIV) therapy for metastatic gastric cancer (mGC).
Authors: Yukiya Narita, Hirokazu Shoji, Sadayuki Kawai, Takuro Mizukami, Michio Nakamura, Toshikazu Moriwaki, Takeharu Yamanaka, Yu Sunakawa, Hisato Kawakami, Tomohiro Nishina, Toshihiro Misumi, Yu Yamashige, Akira Yamashige, Kei Muro
Journal: Journal of Clinical Oncology (2019)

TPS178 Background: Immune checkpoint inhibitors are drugs that block specific proteins produced by the immune system cells, such as T-cells; these proteins prevent T-cells from killing cancer cells. NIV is a standard care for pretreated mGC patients (pts), with increasing clinical use in Japan. Data from retrospective studies on various tumors have shown that after exposure to immune checkpoint inhibitors, the objective response rate to CTx potentially improves; however, enough data have not been accumulated. Although there are no recommended CTx regimen following NIV therapy, in a clinical setting, an irinotecan or oxaliplatin combination regimen (limited to cisplatin-refractory or cisplatin-intolerant pts) is frequently used as post-NIV CTx. This multicenter observational study aims to evaluate the efficacy and safety of CTx in NIV-refractory or NIV-intolerant mGC pts. Methods: We prospectively collect clinical and imaging data from NIV-pretreated mGC pts; these pts will be treated with cytotoxic agents. Pts who meet inclusion criteria A (histologically proven mGC pretreated with NIV, prior administration of a combination therapy of fluoropyrimidine plus platinum and taxanes, and written informed consent) at primary registration are registered. After primary registration, pts who meet inclusion criteria B [Eastern Cooperative Oncology Group Performance Status (ECOG PS 0-2), refractory or intolerant to NIV; prior administration of irinotecan monotherapy or oxaliplatin combination regimens and prior use of cisplatin; evaluable lesions according to RECIST ver. 1.1] at formal registration are registered. The primary endpoint is overall survival of NIV-pretreated mGC pts after CTx. For this study, we require 146 pts, with bilateral alpha = 0.05 and beta = 0.10, with a median threshold survival of 4.0 months and an expected median survival of 6.0 months. Therefore, we plan to enroll 200 pts, considering exclusions from the analysis; since May 2018, we have enrolled 27 pts. Clinical trial information: UMIN000032182.
Reporting of <i>R</i><sup>2</sup> Statistics for Mixed-Effects Regression Models—Reply
Authors: Magi Andorra, Elena H. Martinez-Lapiscina
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Неалкогольна жирова хвороба печінки в дітей: сучасний погляд на можливості діагностики та лікування (II частина)
Authors: Y.M. Stepanov, A.Ye. Abaturov, N.Y. Zavgorodnya, I.Yu. Skirda
Journal: GASTROENTEROLOGY (2020)

У II частині висвітлені методи дослідження та лікування неалкогольної жирової хвороби печінки в дітей, які базуються на принципах доказової медицини. Ультразвукове дослідження печінки вважається найпоширенішим способом діагностики неалкогольної жирової хвороби печінки в дітей й дорослих завдяки безпечності, доступності, відносно низької вартості. Чутливість цього методу у виявленні стеатозу печінки помірного та значного ступеня в дітей становить 79,7 %, специфічність — 86,2 %. Але високий рівень кореляції з даними гістологічних досліджень спостерігається лише у випадках жирової інфільтрації понад 20 % гепатоцитів.На теперішній час біопсія залишається єдиним способом верифікації діагнозу неалкогольної жирової хвороби печінки та золотим стандартом у визначенні ступеня пошкодження печінкової тканини, гістологічної активності запалення та фіброзу.Головною метою лікування неалкогольної жирової хвороби печінки є попередження розвитку термінальних стадій захворювання. Основними напрямками медикаментозного втручання є корекція метаболічних порушень, відновлення чутливості до інсуліну й гепатопротекція.Стрімке зростання поширеності, прогредієнтний перебіг неалкогольної жирової хвороби печінки з можливістю формування цирозу печінки й гепатоцелюлярної карциноми вимагають своєчасної діагностики даного захворювання в дітей. У зв’язку з відсутністю специфічної симптоматики неалкогольної жирової хвороби печінки діагностичному скринінгу підлягають діти з наявністю факторів ризику. Ожиріння є провідним показанням до проведення діагностичного пошуку неалкогольної жирової хвороби печінки в дітей. Виявлення генетичних предикторів розвитку неалкогольної жирової хвороби печінки дозволяє відокремити групу пацієнтів, що потребують активного моніторингу через імовірність прогресування захворювання. Установлення діагнозу неалкогольної жирової хвороби печінки можливе після ретельного виключення інших причин розвитку стеатозу з урахуванням віку дитини та відповідних клініко-лабораторних даних. Застосування візуалізаційних методик дозволяє виявити й кількісно оцінити мінімальний ступінь стеатозу, але біопсія печінки залишається золотим стандартом у визначенні ступеня пошкодження печінкової тканини та фіброзу. Модифікація способу життя є першою лінією лікування неалкогольної жирової хвороби печінки в дітей. Медикаментозна корекція із застосуванням інсуліносенситайзерів, гепатопротекторів, антиоксидантів, пре- і пробіотиків призначається у випадках неефективності терапії першої лінії.
Implementing the USPSTF Recommendations on Prevention of Perinatal Depression—Opportunities and Challenges
Authors: Jennifer N. Felder
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 12149: Severe Obesity, but not Overweight, is Associated With Short- and Long-term Decreased Mortality in Patients With Type 2 Diabetes Hospitalized for Acute Decompensated Heart Failure: Findings From the Gulf-care
Authors: Charbel Abi Khalil, Kadhim Suleiman, Rajvir Singh, Nidal Asaad, Amin Jayyousi, Jassim Al Suwaidi
Journal: Circulation (2016)

Introduction: A U-shaped relationship has been reported between BMI and cardiovascular events among patients with acute decompensated heart failure (ADHF). Hypothesis: We hypothesized that an obesity paradox governs the relationship between BMI and mortality in patients with type 2 diabetes (T2D) and ADHF. Methods: The Gulf-CARE (Gulf aCute heArt failuRe rEgistry) is a prospective multicenter study of 5005 consecutive patients hospitalized with acute heart failure in 7 Middle Eastern countries. We studied 3-month and 12-month mortality in patients with T2D hospitalized for ADHF according to 5 BMI categories: Underweight (&lt;20 kg/m 2 ), normal weight (referent group, 20-24.9 kg/m 2 ), overweight , (25-29.9 kg/m 2 ), obese (30-34.9 kg/m 2 ) and severely obese (&gt;=35 kg/m 2 ). Results: Among the 5005 patients admitted in the GULF-CARE registry, 2492 (49.8%) had T2D. Underweight patients had a higher 3-month and 12-month mortality risk (OR 2.04, 95% CI [1.02-4.08], p= 0.04; OR 2.44, 95% CI [1.35-4.3], p=0.003; respectively), compared to normal weight. Overweight and obese patients had a mortality risk similar to that of normal weight. However, severe obesity (BMI &gt;=35 kg/m 2 ) was associated with a lower 3-month and 6-month mortality risk (OR 0.53, 95% CI [0.34-0.83], p=0.005; OR 0.58, 95% CI [0.42-0.81]; p=0.01; respectively). After adjustment for several risk variables, including age, gender, hypertension, smoking, dyslipidemia, LVEF, heart rate, ADHF etiology, BP and medications at discharge, the primary outcome was still significantly increased in underweight patients at 3 months and 12 months, and decreased in severely obese patients for the same period. Conclusions: In this cohort of patients with ADHF, a U-shape relationship between BMI and mortality was not found in patients with T2D. Protection against long-term mortality increases in obese patients, reaching a significant peak in severely obese ones. Figure 1: 12-month mortality risk. * p= 0.004; ** p= 0.008
Baseline and longitudinal quantification of lean muscle mass using routine CT measurements prior to resection for pancreatic adenocarcinoma.
Authors: Paul Eliezer Oberstein, Vilma Rosario, Xiaotao Guo, Binsheng Zhao, Jeanine M Genkinger, Michael D. Kluger, John A. Chabot
Journal: Journal of Clinical Oncology (2019)

198 Background: When compared to healthy populations subjects are defined as sarcopenic if they have severe loss of lean muscle mass (LMM). Sarcopenia is associated with poor outcomes in some studies of pancreatic cancer (PDA) but the prevelance remains uncertain in resected patients and there is little data about changes in LMM during neoadjuvant chemotherapy. Muscle mass can be reliably quantified in cancer patients using routine imaging. We analyzed a large cohort of patients undergoing surgery at a high-volume center to quantify LMM at baseline and with treatment, and to determine the association of sarcopenia with tumor histology and outcomes. Methods: We analyzed subjects undergoing surgery for PDA at the Pancreas Center at Columbia University from 2011-2014. We utilized CT scans to measure cross sectional area of muscle at the L3 vertebral body (LMM in cm 2 ) and used height to define a smooth muscle index (SMI-cm/m). Sarcopenia was determined based on SMI &lt; 38.9 for females and &lt; 55.4 for males. In subjects undergoing neoadjuvant chemotherapy, SMI was also calculated on post therapy scans. We collected information on clinical and pathological variables and performed statistical analyses utilizing SAS 9.4 software. Results: Among subjects with available imaging (n = 106) sarcopenia rates at initial staging were high whether they were immediately resectable (52%) or locally advanced (63%). Rates of sarcopenia were higher in males than females (77 vs 38%, p &lt; 0.001). Sarcopenic status was not correlated with survival, tumor stage or grade but was associated with age, gender, and BMI. Among locally advanced subjects who proceeded to surgery after neoadjuvant chemotherapy (n = 40) there was no change in SMI or incidence of sarcopenia following treatment (median 171 days). Conclusions: Sarcopenia is highly prevalent at diagnosis in subjects undergoing surgery for PDA but was not associated with survival, tumor grade or stage in this cohort. Subjects who successfully completed neoadjuvant treatment did not experience significant loss in LMM despite extensive treatment suggesting that lack of change in LMM may assist in predicting favorable response to neoadjuvant therapy in PDA.
Rapid identification of PIK3CA-mutations in lung cancer by using pyrosequencing.
Authors: Verena Schildgen, Jessica Lusebrink, Walburga Engel-Riedel, Erich Stoelben, Oliver Schildgen, Michael Brockmann
Journal: Journal of Clinical Oncology (2012)

e18000 Background: Phospatidylinositol-3-kinases (PI3K) play an important role in various cell processes. Oncogenic mutations in the PIK3CA gene which codes for the catalytic subunit have been identified in various malignancies and activate the PI3K/AKT/mTOR pathway which is a critical driver of tumorigenesis. Methods: We tested 41 tumor samples with known KRAS, BRAF, and EGFR mutation status for the occurence of mutations in the PIK3CA gene using a new commercial pyrosequencing kit. Results: Pyrosequencing revealed 2 mutations (4.9 %) in the PIK3CA gene, one in exon 9 and one in exon 20. Both mutations have not yet been identified in lung tumor tissue. Conclusions: The screening of our small patient cohort by pyrosequencing identified two mutations (4.8 %) in PIK3CA, on in exon 9 (Q546H) and on in exon 20 (M1043T). Both mutations have not yet been described in lung tumours and seem to be rather uncommon mutations. Future Screening of large patient cohorts with pyrosequencing may contribute to the detection of more mutations in lung cancer due to the low limit of detections of this method and may contribute to a better understanding of the interaction of mutations and tumorigenesis.
Contactless cardiac arrest detection using smart devices
Authors: Justin Chan, Thomas Rea, Shyamnath Gollakota, Jacob E. Sunshine
Journal: npj Digital Medicine (2019)

Abstract Out-of-hospital cardiac arrest is a leading cause of death worldwide. Rapid diagnosis and initiation of cardiopulmonary resuscitation (CPR) is the cornerstone of therapy for victims of cardiac arrest. Yet a significant fraction of cardiac arrest victims have no chance of survival because they experience an unwitnessed event, often in the privacy of their own homes. An under-appreciated diagnostic element of cardiac arrest is the presence of agonal breathing, an audible biomarker and brainstem reflex that arises in the setting of severe hypoxia. Here, we demonstrate that a support vector machine (SVM) can classify agonal breathing instances in real-time within a bedroom environment. Using real-world labeled 9-1-1 audio of cardiac arrests, we train the SVM to accurately classify agonal breathing instances. We obtain an area under the curve (AUC) of 0.9993 ± 0.0003 and an operating point with an overall sensitivity and specificity of 97.24% (95% CI: 96.86–97.61%) and 99.51% (95% CI: 99.35–99.67%). We achieve a false positive rate between 0 and 0.14% over 82 h (117,985 audio segments) of polysomnographic sleep lab data that includes snoring, hypopnea, central, and obstructive sleep apnea events. We also evaluate our classifier in home sleep environments: the false positive rate was 0–0.22% over 164 h (236,666 audio segments) of sleep data collected across 35 different bedroom environments. We prototype our proof-of-concept contactless system using commodity smart devices (Amazon Echo and Apple iPhone) and demonstrate its effectiveness in identifying cardiac arrest-associated agonal breathing instances played over the air.
Response to criticisms of the 20 m shuttle run test: deflections, distortions and distractions
Authors: Grant R Tomkinson, Justin J Lang, Luc A Léger, Timothy S Olds, Francisco B Ortega, Jonatan R Ruiz, Mark S Tremblay
Journal: British Journal of Sports Medicine (2019)

In their editorial, Armstrong and Welsman1 suggest that the 20 m shuttle run test (20mSRT) (mis)represents and (mis)interprets youth cardiorespiratory fitness (CRF), and potentially (mis)informs health promotion and clinical practice. Their main arguments are: (a) the 20mSRT only provides an estimate of CRF (ie, peak ![Formula][1]</img> O2) and (b) estimates are ratio-scaled (ie, expressed relative to body mass). In this response we provide several reasons, rooted in evidence, which refute their interpretation of our work. CRF measures the body's capacity to deliver and utilise oxygen for energy transfer to support muscle activity during physical activity.2 The 20mSRT provides a simple, single measure that assesses the integrated responses of the physiological systems' ability to perform progressive aerobic exercise. Unfortunately, it does not provide specific information on the function or contribution of specific systems that can be obtained from a gas analysed peak ![Formula][2]</img> O2 test. The 20mSRT is a good measure of functional exercise capacity that authentically imitates youth physical activities (eg, running, agility) in a natural setting. At the individual level, the 20mSRT is a true indicator of peak ![Formula][3]</img> O2 (absolute or … [1]: /embed/mml-math-1.gif [2]: /embed/mml-math-2.gif [3]: /embed/mml-math-3.gif
Burden of carcinoid heart disease in patients initiating treatment for carcinoid syndrome.
Authors: Vijay N Joish, Raul Perez-Olle, Pablo Lapuerta, Sam Dharba, Jerome Zacks
Journal: Journal of Clinical Oncology (2019)

262 Background: Carcinoid heart disease (CaHD) develops as a complication of uncontrolled carcinoid syndrome (CS) due to overproduction of serotonin. Delayed diagnosis or control of CS may result in a greater prevalence of cardiac involvement. The objective of this study was to determine the burden of CaHD in patients initiating somatostatin analogs (SSA) for CS. Methods: This retrospective study investigated claims for commercially insured adults receiving SSA for CS between 2010 and 2016. Claims were evaluated for markers of CaHD such as tricuspid or pulmonary valve-related disease. Eligible patients had ≥ 1 medical claim for CS, had initiated SSA treatment, were continuously enrolled in their health plan for 30 days prior to SSA initiation and for ≥ 1 year, had no sign of acromegaly, and did not participate in a clinical trial during the study period. Patients were followed as long as they were observed in the dataset. Descriptive statistics examined demographic and treatment characteristics and costs for patients with (cases) and without (controls) a marker for CaHD during the study period. Results: A total of 654 patients with CS met the study criteria, of which 38% (n = 248) already had ≥ 1 marker for CaHD prior to initiating SSA treatment. At least 1 CaHD marker was identified in 46% (n = 185) of patients (cases) during the follow-up period. Except for age, all demographic characteristics were similar between cases and controls (n = 221). Cases were significantly older than controls (mean 67 vs. 64 years, p = 0.004). Average follow-up was 26 months (SD 22.0) for cases and 35 months (SD 24.8) for controls. Average time to observation of first CaHD marker for cases was 16 months (SD 16.7) after SSA initiation; most (84%) had ≥ 2 CaHD markers. Markers of right heart involvement were present in 20% of cases, and aortic or mitral valve involvement in 15% and 24%, respectively. Annual per patient expenditures were significantly higher for cases versus controls (mean [SD]: $51,825 [$70,423] vs $29,068 [$56,454], respectively). Conclusions: This study revealed that CaHD is common among patients with CS both before and after initiating SSA treatment. Early diagnosis and control of CS is necessary to reduce the burden of CaHD.
Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial
Authors: Stefan Alig, Alessandro Pastore, Vindi Jurinovic, Sarah Häbe, Deepak Bararia, Verena Passerini, William Keay, Johannes Hellmuth, Andreas Rosenwald, Wolfram Klapper, Harald Stein, Alfred Feller, German Ott, Annette M. Staiger, Heike Horn, Martin-Leo Hansmann, Christiane Pott, Roswitha Forstpointner, Wolf-Karsten Hofmann, Norbert Schmitz, Georg Hess, Michael Unterhalt, Martin H. Dreyling, Anna-Katharina Zoellner, Christian Schmidt, Eva Hoster, Wolfgang Hiddemann, Oliver Weigert
Journal: Blood (2018)
Troponin C is the Major Shrimp Allergen Among Chinese Patients with Shellfish Allergy
Authors: Christine YY. Wai, Nicki YH. Leung, Agnes Sze Yin Leung, Maco CY. Lam, Kary Xu, Yuki Shum, Gary Wing Kin Wong, Ting Fan Leung
Journal: Journal of Allergy and Clinical Immunology (2019)